Cardiovascular adverse effects of antipsychotic drugs

Drug Safety

Volumn 23, Issue 3, 2000, Pages 215-228

  Buckley, N A ^a   Sanders, P ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CALMODULIN; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIURETIC AGENT; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; POTASSIUM CHANNEL; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SODIUM CHANNEL; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; ZIPRASIDONE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TACHYCARDIA;

EID: 0033811846     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023030-00004     Document Type: Review

References (80)

1. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland
2. Thioridazine HCL (Mellaril): Its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities
3. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials
4. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol
5. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
6. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators
7. Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study
8. Adverse effects of the atypical antipsychotics
9. Polyserositis associated with clozapine treatment
10. Myocarditis and cardiomyopathy associated with clozapine
11. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain
12. Measurement of heart rate variability: A clinical tool or a research toy?
13. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart)
14. Heart rate variability in left ventricular dysfunction and heart failure: Effects and implications of drug treatment
15. Heart rate variability and progression of coronary atherosclerosis
16. Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine
17. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?
18. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients
19. Psychotropic drug use and the risk of hip fracture
20. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents
21. Long QT syndromes and torsade de pointes
22. The long QT syndrome: Ion channel diseases of the heart
23. + channels as pharmacological targets: Present and future implications
24. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
25. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
26. Torsade de pointes: Mechanisms and management
27. Experimental models of torsade de pointes
28. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II
29. An analysis of the time relations of electrocardiograms
30. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: Classification, differential diagnosis, and implications for therapy
31. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes
32. Clinical use of class 1c antiarrhythmic drugs
33. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report
34. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death
35. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle-branch block but structurally normal hearts
36. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation
37. + channel
38. + channel mutation causing both long-QT and Brugada syndromes
39. An unusual cause of arrhythmic syncope: The Brugada syndrome
40. A survey in the incidence of fight bundle branch block with ST elevation among normal population
41. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts
42. Is the Brugada syndrome a distinct clinical entity?
43. ECG predictors of arrhythmias after tricyclic and thioridazine overdose
44. The molecular and ionic specificity of antiarrhythmic drug actions
45. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
46. The risk of myocardial infarction associated with antihypertensive drug therapies
47. Review of postinfarct treatment with verapamil: Combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction
48. Toxic cardiomyopathy: The effect of antipsychotic-antidepressant drugs and calcium on myocardial protein degradation and structural integrity
49. Fatal myocardial infarction and use of psychotropic drugs in young women
50. Psychotropic drugs and myocardial infarction: Cause for or caused by panic
51. Could the interaction of neuroleptics with calmodulin be an 'explanation' of the psychotropic effects?
52. Improvement of myocardial function by trifluoperazine, a calmodulin antagonist, after acute coronary artery occlusion and coronary revascularization
53. Cardiomyopathy associated with clozapine
54. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
55. Fatal cardiac event following initiation of risperidone therapy
56. Antipsychotic drugs: Prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue
57. Receptor pharmacology of neuroleptics: Relation to clinical effects
58. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers
59. Postural hypotension in chronically medicated schizophrenics
60. Electrocardiographic changes in patients receiving neuroleptic medication
61. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease
62. Post-mortem antipsychotic drug concentrations and unexplained deaths
63. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics
64. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
65. Torsade de pointes associated with intravenous haloperidol in critically ill patients
66. Clozapine induced atrial fibrillation
67. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics
68. Antipsychotic drugs in overdose: Practical management guidelines
69. Fatal toxicity of drugs used in the treatment of psychotic illnesses
70. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype
71. Low penetrance in the long-QT syndrome: Clinical impact
72. Metabolism of thioridazine in the elderly
73. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites
74. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature
75. Clinical pharmacokinetics of antipsychotics
76. Clinically significant interactions of psychotropic agents with antipsychotic drugs
77. Interactions between antipsychotic and antihypertensive drugs
78. Sudden unexplained death in psychiatric in-patients
79. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart